Abstract

More and more undetermined lung lesions are being identified in routine lung cancer screening. The aim of this study was to try to establish a malignancy prediction model according to the tumor presentations. From January 2017 to December 2018, 50 consecutive patients who were identified with suspicious lung lesions were enrolled into this study. Medical records were reviewed and tumor macroscopic and microscopic presentations were collected for analysis. Circulating tumor cells (CTC) were found to differ between benign and malignant lesions (p = 0.03) and also constituted the highest area under the receiver operation curve other than tumor presentations (p = 0.001). Since tumor size showed the highest sensitivity and CTC revealed the best specificity, a malignancy prediction model was proposed. Akaike information criterion (A.I.C.) of the combined malignancy prediction model was 26.73, which was lower than for tumor size or CTCs alone. Logistic regression revealed that the combined malignancy prediction model showed marginal statistical trends (p = 0.0518). In addition, the 95% confidence interval of combined malignancy prediction model showed less wide range than tumor size ≥ 0.7 cm alone. The calculated probability of malignancy in patients with tumor size ≥ 0.7 cm and CTC > 3 was 97.9%. By contrast, the probability of malignancy in patients whose tumor size was < 0.7 cm, and CTC ≤ 3 was 22.5%. A combined malignancy prediction model involving tumor size followed by the CTC count may provide additional information to assist decision making. For patients who present with tumor size ≥ 0.7 cm and CTC counts > 3, aggressive management should be considered, since the calculated probability of malignancy was 97.9%.

Highlights

  • Lung cancer is a leading cause of cancer death worldwide

  • Tumor composition was classified into four groups, including pure ground glass opacity (GGO), GGO predominant, solid predominant, and pure solid

  • Twenty-four percent of the patients were identified as pure GGO and GGO predominant, while 72% patients were identified as solid predominant and pure solid lesion

Read more

Summary

Introduction

With regard to lung cancer survival, patients detected in the early stages have a better prognosis. They are difficult to identify, since there are no obvious clinical symptoms and signs. In the era of lung cancer screening, as more LDCT’s have been done, more undetermined pulmonary lesions have been identified. It has become crucial for clinical practitioners to be able to pick out those lesions, which really need to be managed. No specific image characteristics can be used as malignancy predictors for undetermined lung lesions

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call